MedPath

FORMA THERAPEUTICS, INC.

FORMA THERAPEUTICS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2007-01-01
Employees
101
Market Cap
-
Website
http://www.formatherapeutics.com

Clinical Trials

28

Active:14
Completed:4

Trial Phases

4 Phases

Phase 1:18
Phase 2:8
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (64.3%)
Phase 2
8 (28.6%)
Not Applicable
1 (3.6%)
Phase 3
1 (3.6%)

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2024-01-10
Last Posted Date
2025-06-18
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
50
Registration Number
NCT06198712
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

🇰🇪

KEMRI-Walter-Reed Kericho, Kericho, Kenya

🇰🇪

Ahero Clinical Trials Unit, Kisumu, Kenya, Kisumu, Kenya

and more 12 locations

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2023-07-20
Last Posted Date
2024-10-29
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
46
Registration Number
NCT05953584
Locations
🇮🇳

All India Institute of Medical Sciences (AIIMS), Raipur, Raipur, Chhattisgarh, India

🇮🇳

All India Institute of Medical Sciences-Delhi, Delhi, India

🇮🇳

Nirmal Hospital Pvt. Ltd., Gujarat, India

and more 6 locations

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2023-02-13
Last Posted Date
2024-06-26
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT05725902
Locations
🇺🇸

Emory University Children's Healthcare of Atlanta, Atlanta, Georgia, United States

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Phase 2
Terminated
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
First Posted Date
2022-10-05
Last Posted Date
2024-12-17
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
45
Registration Number
NCT05568225
Locations
🇺🇸

Cedars-Sinai Medical Center, Plainsboro, New Jersey, United States

🇺🇸

Northwell Health, Plainsboro, New Jersey, United States

🇺🇸

Northwestern Memorial Hospital, Plainsboro, New Jersey, United States

and more 15 locations

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Phase 2
Active, not recruiting
Conditions
Sickle Cell Disease
Thalassemia
Interventions
First Posted Date
2021-08-03
Last Posted Date
2025-05-21
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
60
Registration Number
NCT04987489
Locations
🇺🇸

[Legal] Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

UCSF Oakland Benioff ChildHosp, Oakland, California, United States

🇺🇸

[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County, Orange, California, United States

and more 13 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath